SAN FRANCISCO, CA, USA and SUZHOU, China I October 16, 2024 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...
BETHESDA, MD & GAITHERSBURG, MD, USA I October 16 2024 I Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools ...
Potential best-in-class non-opioid Nav1.8 inhibitor, LTG-305 aims to provide safer treatment for chronic pain by targeting underlying mechanisms of pain at ...
Novel SEQ SIFTER™ discovery platform used to re-engineer original human IgE antibodies into IgG antibodies to block binding and protect against peanut allergen ...
Transition into clinical-stage development marks a significant corporate and R&D milestone.
ADI-001 clinical development program now addresses six autoimmune diseases. Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be ...
PARIS, France I October 17, 2024 I Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to ...
PRINCETON, NJ, USA I October 15, 2024 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...
ISM-001 is a potential first-in-class antibody that may lead to a new treatment pathway for patients with peripheral arterial ...
MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients ...
LEXINGTON, MA, USA and AMSTERDAM, The Netherlands I October 15, 2024 I uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
HAMBURG, Germany I October 15, 2024 I Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback